Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr 26;72(8):1350-1357.
doi: 10.1093/cid/ciaa222.

High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue  1   2 , Hu Xie  1 , Wendy M Leisenring  1 , Louise E Kimball  3 , Sonia Goyal  3 , Lisa Chung  3 , Rachel Blazevic  3 , Byron Maltez  3 , Anna Edwards  1 , Ann E Dahlberg  1 , Rachel B Salit  1 , Colleen Delaney  1   4 , Steven A Pergam  1   3 , Michael Boeckh  1   3 , Filippo Milano  1 , Joshua A Hill  1   3
Affiliations

High Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis

Elisabetta Xue et al. Clin Infect Dis. .

Abstract

Background: Cord blood transplant (CBT) recipients have a high incidence of herpes zoster (HZ) in the context of short-term peritransplant antiviral prophylaxis. In 2009, international guidelines recommended HZ prophylaxis for at least 1 year after hematopoietic cell transplant. The impact of longer-term antiviral prophylaxis on HZ incidence after CBT is unknown.

Methods: We retrospectively analyzed varicella zoster virus (VZV)-seropositive CBT recipients who were transplanted between 2006 and 2016. We abstracted HZ events and other variables for up to 5 years post-CBT. We calculated the cumulative incidence of HZ and used Cox proportional hazards regression to identify variables associated with HZ.

Results: The study cohort consisted of 227 patients. Among 1-year survivors, 91% were still receiving prophylaxis, for a median duration of 20.6 months. HZ occurred in 44 patients (19%) at a median of 23.6 months. The cumulative incidence of HZ by 1 year after CBT was 1.8% (95% confidence interval [CI], .1%-4%), but increased to 26% (95% CI, 19%-33%) by 5 years. In a multivariable analysis, acute graft-vs-host disease was associated with increased risk, whereas antiviral prophylaxis was associated with reduced risk for HZ (adjusted hazard ratio, 0.19 [95% CI, .09-.4]). There was no association between CD4+ T-cell counts at 1 year post-CBT and subsequent risk for HZ.

Conclusions: We found a high incidence of HZ after CBT despite antiviral prophylaxis for > 1 year. Based on these findings, we suggest longer duration of prophylaxis for HZ after CBT. Compliance with antiviral prophylaxis, VZV-specific immune monitoring, and vaccination to mitigate HZ after CBT also require further study.

Keywords: antiviral; cord blood; hematopoietic cell transplant; prophylaxis; varicella zoster virus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials (CONSORT) diagram. Fifty-nine patients who received Varivax were excluded a priori. Abbreviations: CBT, cord blood transplant; VZV, varicella zoster virus.
Figure 2.
Figure 2.
Cumulative incidence plot of time to herpes zoster (HZ) episode and mortality after cord blood transplant. In this plot, the lower curve shows the cumulative incidence of HZ, with death and subsequent hematopoietic cell transplant (HCT) treated as competing risk events. The upper curve shows the cumulative incidence of overall mortality in patients who did not develop HZ, and the middle section illustrates the proportion of individuals alive and free of HZ.
See this image and copyright information in PMC

References

    1. Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6:44–9. - PubMed
    1. Yagi T, Karasuno T, Hasegawa T, et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000; 25:1003–5. - PubMed
    1. Grant RM, Weitzman SS, Sherman CG, Sirkin WL, Petric M, Tellier R. Fulminant disseminated varicella zoster virus infection without skin involvement. J Clin Virol 2002; 24:7–12. - PubMed
    1. Onozawa M, Hashino S, Haseyama Y, et al. Incidence and risk of postherpetic neuralgia after varicella zoster virus infection in hematopoietic cell transplantation recipients: Hokkaido Hematology Study Group. Biol Blood Marrow Transplant 2009; 15:724–9. - PubMed
    1. Kanbayashi Y, Matsumoto Y, Kuroda J, et al. Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis. Ann Hematol 2017; 96:311–5. - PubMed

Publication types

Substances